|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
|
27931088 |
2017 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, luseogliflozin has similar efficacy and safety in Japanese people with T2D when meals contain 40% to 55% total energy carbohydrate, but a strict LC diet on this class of drug should be avoided to prevent SGLT2 inhibitor-associated diabetic ketoacidosis.
|
27990776 |
2017 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, a potential side effect that has been reported with SGLT2 inhibitors in patients with T2DM and particularly during off-label use in patients with type 1 diabetes is diabetic ketoacidosis.
|
28099783 |
2017 |
|
Diabetic Ketoacidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although SGLT2 inhibitors are generally well tolerated, they are associated with an increased risk of genital mycotic infections, as well as the potential risk for serious adverse events such as dehydration, development of diabetic ketoacidosis, serious urinary tract infections, and bone fractures.
|
28102030 |
2017 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The total incidence of adverse events (AEs), hypoglycemia, and genital and urinary infections were also similar to placebo, while an increased incidence of diabetic ketoacidosis (DKA) (n = 16) was seen in SGLT-2 inhibitors group.
|
28276512 |
2017 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly.
|
28323955 |
2017 |
|
Diabetic Ketoacidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We report the occurrence of diabetic ketoacidosis (DKA) in 3 patients with type 2 diabetes recently commenced on SGLT-2 inhibitors.
|
28437153 |
2017 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System.
|
28500396 |
2017 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials.
|
28570924 |
2017 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
There have been increasing cases of diabetic ketoacidosis, and specifically the euglycemic manifestation, associated with SGLT2 inhibitors use.
|
28597228 |
2017 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is important for emergency physicians to be aware of this phenomenon in all SGLT2-inhibitor users, as a delay in the diagnosis of DKA can be life threatening.
|
29157798 |
2018 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
There was no significant increase in the rate of hypoglycaemia or severe hypoglycaemia; however, SGLT2 inhibitor therapy increased diabetic ketoacidosis (odds ratio [OR] 3.38) and genital tract infection (OR 3.44).
|
29451721 |
2018 |
|
Diabetic Ketoacidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We found that SGLT2 inhibitor treatment did not increase the risk of DKA compared with DPP-4 inhibitor treatment.
|
29569427 |
2018 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
When insulin dosage is lowered too much, SGLT2 inhibitors can enhance ketogenesis to the extent that the risk of diabetic ketoacidosis increases, particularly in type 1 diabetic patients.
|
29663292 |
2018 |
|
Diabetic Ketoacidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Increased risk of diabetic ketoacidosis (DKA) with uncharacteristically mild-to-moderate glucose elevations (euglycemic DKA) is associated with the use of all the approved SGLT2 inhibitors.
|
29916741 |
2018 |
|
Diabetic Ketoacidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Agents in the sodium glucose co-transporter-2 inhibitor (SGLT-2) class demonstrate the greatest promise in correcting hyperglycaemia, but there are safety concerns in relation to the risk of diabetic ketoacidosis.
|
30209797 |
2018 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
SGLT2 inhibitors in high and moderate doses can achieve a better outcome on efficacy, but may induce a higher risk of adverse events, especially DKA.
|
30565398 |
2019 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on their history of medications taken before admission, subjects were classified as either users or non-users of SGLT2 inhibitors and their clinical characteristics of DKA were compared.
|
30639566 |
2019 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
When compared with placebo, SGLT2 inhibitors were found to be significantly protective against AKI (RR=0.59; 95% CI 0.39 to 0.89; I<sup>2</sup>=0.0%), while no difference was found for DKA (RR 0.66; 95% CI 0.30 to 1.45, I<sup>2</sup>=0.0%), UTI (RR 1.02; 95% CI 0.95 to 1.09, I<sup>2</sup>=0.0%) or bone fracture (RR 0.87; 95% CI 0.69 to 1.09, I<sup>2</sup>=1.3%).
|
30813108 |
2019 |
|
Diabetic Ketoacidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Diabetic ketoacidosis (DKA) has been associated with the use of sodium glucose cotransporter 2 inhibitors (SGLT2is).
|
30835263 |
2019 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several other SGLT2 inhibitors have been associated with increased frequency of diabetic ketoacidosis (DKA).
|
30880915 |
2019 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adverse Drug Reaction Profile of SGLT2 Inhibitor-Associated Diabetic Ketosis/Ketoacidosis in Singapore and their Precipitating Factors.
|
31065934 |
2019 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic ketoacidosis occurred more often with SGLT-2 inhibitors and SGLT-1/2 inhibitors vs placebo, although the incidence was generally low.
|
31081593 |
2019 |
|
Diabetic Ketoacidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
They have carried out a metanalysis showing a 3.5-fold increase in the risk of diabetic ketoacidosis (DKA) in patients with type 1 diabetes under treatment with SGLT2 inhibitors.
|
31334593 |
2019 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report a novel complication of hypoglycemia that occurred during the course of treatment of SGLT2 inhibitor-induced DKA in a patient with type 2 diabetes mellitus (T2DM) on the dapagliflozin-metformin combination.
|
31489272 |
2019 |